Stock Yards Bank & Trust Co. Has $1.80 Million Position in Gilead Sciences, Inc. $GILD

Stock Yards Bank & Trust Co. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 40.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,635 shares of the biopharmaceutical company’s stock after selling 10,135 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Gilead Sciences were worth $1,796,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Corundum Trust Company INC acquired a new position in Gilead Sciences in the third quarter worth approximately $26,000. MTM Investment Management LLC lifted its stake in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Millstone Evans Group LLC lifted its stake in shares of Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares during the last quarter. Y.D. More Investments Ltd acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at $37,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.9%

Shares of NASDAQ:GILD opened at $138.80 on Wednesday. The company has a market cap of $172.28 billion, a P/E ratio of 20.50, a P/E/G ratio of 1.83 and a beta of 0.39. The stock’s 50-day moving average is $145.10 and its 200-day moving average is $130.01. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. HSBC lifted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 price objective on shares of Gilead Sciences in a report on Wednesday, February 11th. Finally, The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $157.81.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition strengthens oncology pipeline: Gilead agreed to acquire Tubulis for up to $5.0B ($3.15B upfront, up to $1.85B in milestones), adding a next‑generation ADC platform and lead candidate TUB‑040 (Phase 1b/2 for platinum‑resistant ovarian cancer and NSCLC). The transaction is expected to close in Q2 2026 and Tubulis will operate inside Gilead post‑close — a tangible pipeline boost that can extend future oncology revenue. Business Wire
• Positive Sentiment: Analyst support: Bernstein put a Buy on Gilead, signaling conviction that recent M&A and pipeline moves improve medium‑term prospects — a positive endorsement that can underpin investor confidence. Globe and Mail
• Neutral Sentiment: Street reactions are mixed: Some banks raised price targets (RBC nudged its target higher to $123) but maintained conservative ratings, leaving implied upside limited from some analysts’ perspectives. That keeps expectations calibrated even as the company spends on deals. MarketScreener
• Neutral Sentiment: Macro/sector context: Broad market weakness today and healthcare sector headlines (Medicare rate moves, sector M&A activity) are weighing on stocks generally; Gilead’s move is part of a wider Q1 surge in pharma M&A. Yahoo / Sector roundup
• Negative Sentiment: Execution and strategy concerns: Commentary frames recent M&A as partly defensive — “more about survival” — and investors may be worried about integration risk, high upfront cost and contingent milestones. These concerns can pressure the share price in the short term despite long‑term pipeline logic. Moby / Yahoo

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the transaction, the chief financial officer directly owned 179,191 shares in the company, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 299,280 shares of company stock valued at $42,820,550 in the last three months. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.